Tilray Medical Partners With Molteni to Expand Access to Medical Marijuana in Italy

Under the agreement, Tilray’s wholly-owned subsidiary, FL Group, will work with Molteni to increase availability of EU-GMP certified cannabis therapies while also boosting education for healthcare providers. Molteni, which specializes in pain management and substance dependence treatments, will leverage its extensive network of pharmaceutical, medical, and scientific professionals to promote understanding of medical marijuana in pain care. Rajnish Ohri, Tilray Brands’ managing director for international markets, said the partnership combines FL Group’s regulatory and distribution expertise with Molteni’s “scientific leadership” to both broaden patient access and enhance practitioner knowledge. The goal, Ohri added, is to ensure physicians have the resources needed to help patients seeking effective pain management solutions.

Tilray Medical currently operates in Germany, Italy, Portugal, Poland, and the United Kingdom, and supplies medical marijuana products in 20 countries. The company was among the first licensed producers of medical marijuana in Canada and went on to establish Europe’s first GMP-certified cannabis production facilities in Portugal and Germany.

Founded in 1892 and headquartered in Florence, Molteni has a global presence in over 40 countries and is recognized as a specialty pharma leader in pain therapeutics and addiction treatments. The collaboration with Tilray marks a significant move in Italy’s growing medical marijuana market, potentially increasing treatment options for patients dealing with chronic pain and related conditions.